StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$127.16+2.49 (+2.00%)

Close on Nov 18, 2026Market cap $8.23BP/E 123.5Yield –

Protagonist Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Protagonist Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $281.99M, up 34.8% year over year. For fiscal 2025 it was $46.02M, down 89.4% from the year before. The highest annual figure on record is $434.43M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$46.02M-89.4%
FY2024Dec 31, 2024$434.43M+624.1%
FY2023Dec 31, 2023$60.00M+125.7%
FY2022Dec 31, 2022$26.58M-2.8%
FY2021Dec 31, 2021$27.36M-4.4%
FY2020Dec 31, 2020$28.63M+12293.1%
FY2019Dec 31, 2019$231.00K-99.3%
FY2018Dec 31, 2018$30.93M+54.1%
FY2017Dec 31, 2017$20.06M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$213.48M+3749.2%
Q1 FY2026Mar 31, 2026$56.37M+99.0%
Q4 FY2025Dec 31, 2025$7.44M-95.6%
Q3 FY2025Sep 30, 2025$4.71M+0.8%
Q2 FY2025Jun 30, 2025$5.55M+33.1%
Q1 FY2025Mar 31, 2025$28.32M-88.9%
Q4 FY2024Dec 31, 2024$170.64M+184.4%
Q3 FY2024Sep 30, 2024$4.68M–
Q2 FY2024Jun 30, 2024$4.17M–
Q1 FY2024Mar 31, 2024$254.95M–
Q4 FY2023Dec 31, 2023$60.00M–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$859.00K-62.1%
Q1 FY2022Mar 31, 2022$25.72M+315.6%
Q4 FY2021Dec 31, 2021$8.62M+52.5%
Q3 FY2021Sep 30, 2021$10.29M-21.6%
Q2 FY2021Jun 30, 2021$2.27M-16.7%
Q1 FY2021Mar 31, 2021$6.19M+49.5%
Q4 FY2020Dec 31, 2020$5.65M+262.2%
Q3 FY2020Sep 30, 2020$13.11M+457.3%
Q4 FY2019Dec 31, 2019$2.72M-55.6%
Q3 FY2019Sep 30, 2019$4.14M-64.5%
Q1 FY2019Mar 31, 2019$1.56M-85.5%
Q4 FY2018Dec 31, 2018$2.35M-79.1%
Q3 FY2018Sep 30, 2018$6.12M-30.3%
Q2 FY2018Jun 30, 2018$11.67M–
Q1 FY2018Mar 31, 2018$10.78M–
Q4 FY2017Dec 31, 2017$11.28M–
Q3 FY2017Sep 30, 2017$8.78M–
Q3 FY2016Sep 30, 2016$0–

More Protagonist Therapeutics figures

See a number that looks wrong?